Compare Ascendis Pharma A/S (ASND) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Capri Holdings Ltd — how do they compare? Ascendis Pharma A/S trades at $254.76 (market cap $16.67B), while Capri Holdings Ltd trades at $15.48 (market cap $1.75B). The key difference: Ascendis Pharma A/S is far larger — about 9.5× Capri Holdings Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | CPRI | |
|---|---|---|
Market Cap | $16.67B | $1.75B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $27.66 |
52-Week Low | $189.74 | $14.98 |
Enterprise Value | $17.04B | $3.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Capri Holdings (CPRI) trades at $15.47, near its 52-week low, with a bearish technical outlook and recent earnings beats overshadowed by declining revenue and a net loss of $1.18 billion in 2025. The company faces challenges in its core Michael Kors brand, with revenue forecasts cut and a high debt-to-asset ratio of 28.79% as of 2025. Despite a consensus price target of $19.60, analyst sentiment is mixed, with 44% buy ratings but significant hold recommendations.
The stock's investment appeal hinges on a successful turnaround, with potential upside from margin improvements and Jimmy Choo growth, but risks include persistent revenue declines, luxury market softness, and execution uncertainties. Near-term volatility is likely as the company navigates brand revamps and inventory issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
